Intra-Cellular Therapies Presents Data on Antitumor Effects of Phosphodiesterase I Inhibition in a Preclinical Colorectal Cancer Model at the 2021 American Association for Cancer Research ...
Intra-Cellular Therapies Inc. (ITCI)
Last intra-cellular therapies inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intracellulartherapies.com/investor-relations
Company Research
Source: GlobeNewswire
Our research has demonstrated that the phosphodiesterase type 1 (PDE1) enzyme modulates the immune system by reducing macrophage and microglial activity with demonstrated effects in neuroinflammatory conditions, cancer and cardiac diseases. Preclinical findings describing the antitumor effects of PDE1 Inhibitors when administered in conjunction with checkpoint inhibitor immunotherapy are being presented at the American Association for Cancer Research (AACR) virtual annual meeting. Our PDE1 platform consists of a portfolio of PDE I inhibitors that are being developed for cancer and other diseases. NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) today announced a poster presentation on its PDE1 inhibitor program at the ongoing 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting, which is being held from April 10 - 15, 2021. Details of the poster presentation are as follows: Title: Effects of ITI-214, a Potent and
Show less
Read more
Impact Snapshot
Event Time:
ITCI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ITCI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ITCI alerts
High impacting Intra-Cellular Therapies Inc. news events
Weekly update
A roundup of the hottest topics
ITCI
News
- Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success [Yahoo! Finance]Yahoo! Finance
- Intra-Cellular Therapies drops 2%, prices $500M equity financing [Seeking Alpha]Seeking Alpha
- Intra-Cellular Therapies Prices Public Offering of Common StockGlobeNewswire
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at TD Cowen from $80.00 to $90.00. They now have a "buy" rating on the stock.MarketBeat
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Robert W. Baird from $83.00 to $103.00. They now have an "outperform" rating on the stock.MarketBeat
ITCI
Earnings
- 2/22/24 - Beat
ITCI
Sec Filings
- 4/18/24 - Form 8-K
- 4/18/24 - Form 424B5
- 4/16/24 - Form 8-K
- ITCI's page on the SEC website